Partnerships
Partnerships
Business Cooperation
Partnerships
Partnerships
Home Partnerships
Partnerships
BUSINESS COOPERATION

Leveraging our expertise in the field of protein-protein interactions, we are developing an innovative pipeline featuring small molecule candidates that target apoptotic pathways, as well as next-generation tyrosine kinase inhibitors with first- and best-in-class potential. We are committed to partnering with other complementary organizations that share our vision of bringing meaningful cures to patients with various cancers, hepatitis B, and age-related diseases.

Our current partners are listed below.


  • University of Michigan

    Built upon a long-term academic relationship, we have established research collaborations and exclusive license agreements with the University of Michigan. Our academic collaboration with the University of Michigan enables us to tackle challenging therapeutic targets, gain access to the latest technologies, and enhance our preclinical and clinical studies capabilities, which allows us to accelerate our research and development progress substantially. The University of Michigan also provides us with valuable resources related to clinical services.


  • Unity Biotechnology

    We have a global partnership with Unity to explore apoptosis targeting therapies for the treatment of age-related diseases. Through the collaboration with Unity, we are able to validate our patent portfolio with a library agreement, enhance our research capabilities and expand commercialization rights to global markets and additional therapeutic areas.

  • Merck & Co., Inc.

    We entered into an agreement with MSD to exclusively license certain technology and related patents covering HQP8361 (MK-8033), a c-Met targeting TKI in Australia, Japan and the PRC.